Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
Active, not recruiting · NCT03732950 · Registry updated 2024-04-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 2 | 2024-04-15 | NCT03732950 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jonsson Comprehensive Cancer Center | 115 |
| Merck Sharp & Dohme LLC | 650 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic | Rochester | United States | 664 |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | United States | 126 |
| University of Minnesota/Masonic Cancer Center | Minneapolis | United States | 105 |